SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

Nucynta ER

COLL·COLLEGIUM PHARMACEUTICAL, INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market, approved since 2008 (IR) and 2011 (ER)
Why 4/10
Nucynta ER is already FDA-approved and commercialized with no pending regulatory binary (PDUFA/pivotal readout) in the next 12+ months. Per the rubric, an approved, marketed drug with no imminent new regulatory decision scores 3-5. A score of 4 reflects that while Nucynta ER is part of Collegium's commercial portfolio, it is not the primary growth driver, the company's focus has shifted to its ADHD franchise (Jornay PM, AZSTARYS) and other pain products. The stock does have a near-term catalyst in Q3 earnings (Nov 5, 2026), but that is a quarterly report, not a drug-specific binary.
Actionable Insight NEUTRAL

Nucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.

Price Chart

Loading chart...

Executive Summary

Nucynta ER (tapentadol hydrochloride extended-release) is a Schedule II opioid analgesic that has been FDA-approved since 2011 and is commercialized by Collegium Pharmaceutical (Nasdaq: COLL). It is a mature product in a diversified portfolio that now includes Xtampza ER, Belbuca, Jornay PM, and the recently acquired AZSTARYS (ADHD). With no upcoming regulatory binary for this specific drug, its investment impact is limited, Nucynta is a legacy revenue contributor facing generic erosion rather than a catalyst for COLL shares. The stock itself screens as attractive on valuation (analyst mean target ~$49 vs ~$23 current price, 113% implied upside) but is down ~55% from its 52-week high amid portfolio transition and high short interest (~17% of shares outstanding).

How It Works

Nucynta ER is an extended-release opioid painkiller. Its active ingredient, tapentadol, works in two ways: it activates the brain's opioid receptors (similar to morphine but weaker) and also inhibits the reuptake of norepinephrine, a chemical involved in pain signaling. This dual mechanism makes it effective for moderate to severe chronic pain. It is a Schedule II controlled substance with abuse and addiction risks, carrying an FDA boxed warning for addiction, abuse, misuse, and life-threatening respiratory depression.

Trial Status

Nucynta ER was approved by the FDA on August 25, 2011. Nucynta immediate-release was originally approved on November 20, 2008. The most recent FDA action was a supplemental labeling approval on December 22, 2025 (NDA 022304). The drug is marketed and commercialized; no further clinical trials are underway for this already-approved molecule.

The Two-Sided Case

▲ Bull Case4
Nucynta ER is a well-established branded opioid with a differentiated dual-mechanism profile (mu-opioid agonist + norepinephrine reuptake inhibition) that still generates meaningful revenue
Collegium's analyst consensus is heavily bullish, 12 buy/strong buy vs 2 hold vs 0 sell, with a mean price target of ~$49 (113% upside from ~$23)
COLL trades significantly below its 52-week high ($50.79) and 200-day SMA ($33.83), presenting a potential value entry if the portfolio transition to ADHD succeeds
Short interest is elevated at ~17% of shares outstanding (6.1 days to cover), which could fuel a short squeeze on positive news
▼ Bear Case5
Nucynta ER faces ongoing generic competition from Hikma Pharmaceuticals and other manufacturers, driving revenue erosion as a mature opioid product
COLL stock is down ~55% from its 52-week high of $50.79, trading at $22.96 with a neutral technical score (-11), well below its 200-day SMA
The company took on significant debt to acquire AZSTARYS for $650M, integration risk and debt service could pressure financials
Opioid litigation/pricing and regulatory headwinds remain an overhang for all branded opioid products including Nucynta ER
Earnings estimates have been revised down over the last 90 days, with EPS estimates for 2026 declining from ~$7.78 to ~$7.46

Upcoming Catalysts

  • No upcoming regulatory catalyst for Nucynta ER specifically, it is an already-approved commercial product
  • COLL Q3 2026 earnings report scheduled November 5, 2026 (consensus EPS ~$1.86, revenue ~$216M)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

COLLEGIUM PHARMACEUTICAL, INC 8-K COLL ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 accessdata.fda.gov3 sec.gov4 sec.gov